It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

And, regardless of whether Merck enters the 2025-2026 RSV season with clesrovimab as planned, “2025 will be a year of growth for Beyfortus,” the CFO stressed. Since its approval last July ...

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

In the RSV market for infants, AstraZeneca and Sanofi’s Beyfortus leads the way. It achieved sales of 547 million euros ($592 million) in 2023. While cross-trial comparisons carry inherent ...

Beyfortus® is the first immunization designed for all infants to help prevent RSV lower respiratory tract disease through their first RSV season. Beyfortus® is also indicated for ...

Women will have the choice to either take the Abrysvo vaccine during pregnancy or have their newborn vaccinated with Beyfortus. Currently, the maternal RSV vaccine known as Abrysvo is only ...

Beyfortus is the first long-acting antibody approved in Canada for the prevention of RSV lower respiratory tract disease in newborns and infants through their first RSV season. Sanofi noted that ...

Children’s Hospital of Erlanger is now accepting appointments to receive the Beyfortus respiratory syncytial virus (RSV) vaccine through Children’s General Pediatrics located at the Kennedy Outpatient ...

Shawn Johnson East is an Olympic and Dancing with the Stars champion who earned serious “cool mom” street cred in 2023 when ...

Beyfortus® is the first long-acting antibody approved in Canada for the prevention of RSV lower respiratory tract disease in newborns and infants through their first RSV season.ii As RSV ...

Beyfortus ® is the first immunization designed for all infants to help prevent RSV lower respiratory tract disease through their first RSV season. Beyfortus ® is also indicated for children up ...